Rates of Gastric Ulcer by Endoscopy in Knee Osteoarthritis Patients Receiving LT-NS001 Versus Naprosyn®

NCT ID: NCT01063920

Last Updated: 2011-01-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2/PHASE3

Total Enrollment

534 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-02-28

Study Completion Date

2010-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

LT-NS001 is a prodrug of Naproxen, which is inactive as a cox inhibitor while intact and is rapidly metabolized to Naproxen once absorbed. This trial will compare the rate of gastric ulcer by endoscopy over three months in patients with knee osteoarthritis, with patients receiving either LT-NS001 at a dose which provides comparable dose levels of Naproxen, or Naprosyn® 500mg (an approved treatment for OA).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a double-blind, double-dummy, active-comparator study of LT-NS001 versus Naprosyn® for 12 weeks in patients aged 45-80 with osteoarthritis of the knee who are candidates for ongoing NSAID therapy. The percentage of patients with a gastric ulcer by endoscopy (EGD) at week 12 will be compared. EGD is performed at screening and months 1, 2, and 3. Secondary objectives include assessment of pain in the affected knee by WOMAC questionnaire to demonstrate non-inferior pain control using LT-NS001 as compared to Naprosyn®. Information about gastrointestinal pain and tolerability will be collected.

The length of the study is up to 19 weeks with a 2-3 week screening period, a 12 week treatment period and a 4 week post treatment monitoring period.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Osteoarthritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Caregivers

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LT-NS001

LT-NS001 1200 mg b.i.d. p.o. for 12 weeks

Group Type EXPERIMENTAL

LT-NS001

Intervention Type DRUG

1200 mg b.i.d. p.o. for 12 weeks

Naprosyn®

Naprosyn® 500 mg b.i.d for 12 weeks

Group Type ACTIVE_COMPARATOR

Naprosyn®

Intervention Type DRUG

500 mg b.i.d. p.o. for 12 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LT-NS001

1200 mg b.i.d. p.o. for 12 weeks

Intervention Type DRUG

Naprosyn®

500 mg b.i.d. p.o. for 12 weeks

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Osteoarthritis of knee
* Appropriate candidate for chronic NSAID therapy due to moderate or severe pain on most days in the 28 days before screening for study.

Exclusion Criteria

* Pregnant/Nursing women
* History of GI bleeding, perforation or obstruction
* A documented symptomatic GI ulcer during past 5 years
* Presence of GI ulcer or more than 2 erosions on screening endoscopy
* Allergy to naproxen (or naproxen intolerance), acetylsalicylic acid, or other NSAID drug
Minimum Eligible Age

45 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

PRA Health Sciences

INDUSTRY

Sponsor Role collaborator

Logical Therapeutics

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Logical Therapeutics, Inc.

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jay L Goldstein, MD

Role: PRINCIPAL_INVESTIGATOR

University of Illinois at Chicago, Department of Medicine

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Greystone Medical Research, LLC

Birmingham, Alabama, United States

Site Status

Clinical Research Associates

Huntsville, Alabama, United States

Site Status

Radiant Research

Chandler, Arizona, United States

Site Status

Dedicated Clinical Research Inc.

Surprise, Arizona, United States

Site Status

Radiant Research Inc.

Tucson, Arizona, United States

Site Status

Adobe Gastroenterology Research, LLC

Tucson, Arizona, United States

Site Status

Genova Clinical Research Inc.

Tucson, Arizona, United States

Site Status

Lynn Institute of the Ozarks

Little Rock, Arkansas, United States

Site Status

Orange County Clinical Trials

Anaheim, California, United States

Site Status

Theresa Sligh, MD

Burbank, California, United States

Site Status

Torrance Clinical Research

Lomeita, California, United States

Site Status

West Gastroenterology Associates

Los Angeles, California, United States

Site Status

Facey Medical Center

Mission Hills, California, United States

Site Status

Desert Medical Group

Palm Springs, California, United States

Site Status

Medical Affiliated Research Center Inc.

San Diego, California, United States

Site Status

Cynthia Schaeffer, MD

San Diego, California, United States

Site Status

Medical Associates Research Group

San Diego, California, United States

Site Status

Lynn Institute of the Rockies

Colorado Springs, Colorado, United States

Site Status

Rocky Mountain Center for Clinical Research

Wheat Ridge, Colorado, United States

Site Status

Eastern Clinical Research Unit

Hialeah, Florida, United States

Site Status

Nature Coast Clinical Research

Inverness, Florida, United States

Site Status

Drug Study Institute

Jupiter, Florida, United States

Site Status

University Clinical Research Inc.

Pembroke Pines, Florida, United States

Site Status

Radiant Research

Pinellas Park, Florida, United States

Site Status

Accord Clinical Research LLC

Port Orange, Florida, United States

Site Status

Miami Research Associates

South Miami, Florida, United States

Site Status

Palm Beach Research Center

West Palm Beach, Florida, United States

Site Status

Gold Coast Research LLC

Weston, Florida, United States

Site Status

Thomas Schnitzer, MD

Chicago, Illinois, United States

Site Status

Welborn Clinic

Evansville, Indiana, United States

Site Status

MediSphere Medical Research Center LLC

Evansville, Indiana, United States

Site Status

Venture Resource Group Inc.

Mission, Kansas, United States

Site Status

Pinnacle Medical Research

Overland Park, Kansas, United States

Site Status

Delta Research Partners LLC

Bastrop, Louisiana, United States

Site Status

SNBL Clinical Pharmacology Center

Baltimore, Maryland, United States

Site Status

Metropolitan Gastroenterolgy Group PC

Chevy Chase, Maryland, United States

Site Status

Arthritis and Osteoporosis Cener of Maryland

Frederick, Maryland, United States

Site Status

MidAtlantic Medical Research Centers/Bean Medical Center

Hollywood, Maryland, United States

Site Status

Dynamic Clinical Research

Kansas City, Missouri, United States

Site Status

Sundance Clinical Research

St Louis, Missouri, United States

Site Status

Montana Health Research Institute Inc.

Billings, Montana, United States

Site Status

Advanced Biomedical Research of America

Las Vegas, Nevada, United States

Site Status

Affiliated Clinical Research Inc.

Las Vegas, Nevada, United States

Site Status

Clifton-Wallington Medical Group

Clifton, New Jersey, United States

Site Status

Research Across America

New York, New York, United States

Site Status

Allergy Asthma Immunology of Rochester Research Center

Rochester, New York, United States

Site Status

Carolina Digestive Health Associates PA

Charlotte, North Carolina, United States

Site Status

Peters Medical Research LLC

High Point, North Carolina, United States

Site Status

Wake Research Associates

Raleigh, North Carolina, United States

Site Status

Radiant Research-Akron

Akron, Ohio, United States

Site Status

Consultants for Clinical Research

Cincinnati, Ohio, United States

Site Status

Health Research of Oklahoma

Oklahoma City, Oklahoma, United States

Site Status

Lynn Health Science Institute

Oklahoma City, Oklahoma, United States

Site Status

Sooner Clinical Research

Oklahoma City, Oklahoma, United States

Site Status

Clinical Research Associates LLC

Oklahoma City, Oklahoma, United States

Site Status

Keith Klatt, MD

Portland, Oregon, United States

Site Status

Altoona Center for Clinical Research

Duncansville, Pennsylvania, United States

Site Status

Corsicana Medical Research PLLC

Corsicana, Texas, United States

Site Status

Galenos Research

Dallas, Texas, United States

Site Status

Clinical Trial Network

Houston, Texas, United States

Site Status

Houston Endoscopy and Research Center

Houston, Texas, United States

Site Status

Houston Medical Research Associates

Houston, Texas, United States

Site Status

Quality Research Inc.

San Antonio, Texas, United States

Site Status

Arthritis and Osteoporosis Clinic Research Center of Central Texas

Waco, Texas, United States

Site Status

Physicians Research Options LLC

Draper, Utah, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

LT-NS001-003

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Knee Injection RCT
NCT03694821 TERMINATED PHASE4